Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types. It acts as a central nervous system depressant.
### Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
* Off-label uses include other seizure disorders and anxiety.
### Adult Dosing
* **LGS:** Initial dose: 5 mg twice daily.
* Titrate dose upwards by 5-10 mg every week based on clinical response and tolerability.
* Usual maintenance dose: 10-20 mg twice daily.
* Maximum recommended dose: 20 mg twice daily (40 mg/day).
### Pediatric Dosing
* **LGS (2 years and older):**
* Initial dose: 5 mg twice daily.
* Titrate dose upwards by 5-10 mg every week based on clinical response and tolerability.
* Usual maintenance dose: 10-20 mg twice daily.
* Maximum recommended dose: 20 mg twice daily (40 mg/day).
* **Use in children younger than 2 years is not recommended due to insufficient data.**
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider starting with a lower dose and titrating slowly.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider starting with a lower dose and titrating slowly.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, aggression, constipation, vomiting, fatigue, gait disturbance, irritability.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms (if stopped abruptly), respiratory depression (especially when used with other CNS depressants).
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, barbiturates):** Increased risk of sedation, respiratory depression, and potentially fatal outcomes. Coadministration should be approached with extreme caution or avoided.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam concentrations. Monitor for increased adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations. Monitor for decreased efficacy.
* **Certain Antiepileptic Drugs (e.g., valproic acid):** Can increase clobazam plasma concentrations. Monitor for increased adverse effects.
### Monitoring
* Monitor for somnolence, fatigue, dizziness, and cognitive impairment.
* Assess for behavioral changes, including aggression and suicidal ideation.
* Monitor for signs of withdrawal if discontinuation is planned.
* Regularly assess seizure frequency and severity.
* Monitor for signs of severe skin reactions.
### Clinical Pearls
* Clobazam is a 1,5-benzodiazepine and has a longer half-life than many other benzodiazepines.
* Withdrawal symptoms can occur if clobazam is stopped abruptly, especially after prolonged use. Tapering is recommended.
* Due to the risk of serious skin reactions, patients should be advised to discontinue clobazam and seek immediate medical attention if a rash develops.
* The risk of dependence and abuse is present with benzodiazepines.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making clinical decisions. Local protocols may vary.*
